Current perceptions of cardiovascular gene therapy

Victor J. Dzau, Kevin Beatt, Giulio Pompilio, Karen Smith

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Due to differences in their knowledge base, scientists, health care professionals, and the general public have varying perceptions of the expectations and risks of using gene therapy for the treatment of cardiovascular disease. Gene therapists are aware of the importance of selecting the right vector, the right gene, and the right administration procedure for a specific application and for characterization of the heterogeneity of the physiologic response to gene expression. They also recognize the need for large-scale clinical trials to demonstrate short- and long-term safety, in addition to efficacy, for widespread acceptance. Interventional cardiologists are more likely to judge a therapy primarily on its ability to improve cardiovascular pathophysiology and function, although they too will demand safety data. Once convinced of the benefits of a gene therapy, interventional cardiologists will rely on regulatory and reimbursement authorities to approve the procedure. Attitudes of less-specialized physicians toward gene therapy and, specifically, therapeutic angiogenesis will be influenced by the level of clinical trial activity in their country and opinions expressed in the media. However, all will want safety and efficacy data as well as clear guidance on the type of patients who should be referred for treatment. Nurses' roles are set to expand with the introduction of gene-based therapies; most will need further genetics education to rise to these challenges with confidence. The success of a gene therapy will also rely on patients' perceptions and their willingness to receive the treatment. Any misconceptions based on unreliable information sources need to be addressed.

Original languageEnglish
JournalThe American Journal of Cardiology
Volume92
Issue number9 SUPPL. 2
DOIs
Publication statusPublished - Nov 7 2003

Fingerprint

Genetic Therapy
Safety
Clinical Trials
Therapeutics
Aptitude
Knowledge Bases
Nurse's Role
Genes
Cardiovascular Diseases
Delivery of Health Care
Physicians
Gene Expression
Education
Cardiologists

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Current perceptions of cardiovascular gene therapy. / Dzau, Victor J.; Beatt, Kevin; Pompilio, Giulio; Smith, Karen.

In: The American Journal of Cardiology, Vol. 92, No. 9 SUPPL. 2, 07.11.2003.

Research output: Contribution to journalArticle

Dzau, Victor J. ; Beatt, Kevin ; Pompilio, Giulio ; Smith, Karen. / Current perceptions of cardiovascular gene therapy. In: The American Journal of Cardiology. 2003 ; Vol. 92, No. 9 SUPPL. 2.
@article{574443f7d0ce4f2c92f380a2033ae07e,
title = "Current perceptions of cardiovascular gene therapy",
abstract = "Due to differences in their knowledge base, scientists, health care professionals, and the general public have varying perceptions of the expectations and risks of using gene therapy for the treatment of cardiovascular disease. Gene therapists are aware of the importance of selecting the right vector, the right gene, and the right administration procedure for a specific application and for characterization of the heterogeneity of the physiologic response to gene expression. They also recognize the need for large-scale clinical trials to demonstrate short- and long-term safety, in addition to efficacy, for widespread acceptance. Interventional cardiologists are more likely to judge a therapy primarily on its ability to improve cardiovascular pathophysiology and function, although they too will demand safety data. Once convinced of the benefits of a gene therapy, interventional cardiologists will rely on regulatory and reimbursement authorities to approve the procedure. Attitudes of less-specialized physicians toward gene therapy and, specifically, therapeutic angiogenesis will be influenced by the level of clinical trial activity in their country and opinions expressed in the media. However, all will want safety and efficacy data as well as clear guidance on the type of patients who should be referred for treatment. Nurses' roles are set to expand with the introduction of gene-based therapies; most will need further genetics education to rise to these challenges with confidence. The success of a gene therapy will also rely on patients' perceptions and their willingness to receive the treatment. Any misconceptions based on unreliable information sources need to be addressed.",
author = "Dzau, {Victor J.} and Kevin Beatt and Giulio Pompilio and Karen Smith",
year = "2003",
month = "11",
day = "7",
doi = "10.1016/S0002-9149(03)00964-0",
language = "English",
volume = "92",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9 SUPPL. 2",

}

TY - JOUR

T1 - Current perceptions of cardiovascular gene therapy

AU - Dzau, Victor J.

AU - Beatt, Kevin

AU - Pompilio, Giulio

AU - Smith, Karen

PY - 2003/11/7

Y1 - 2003/11/7

N2 - Due to differences in their knowledge base, scientists, health care professionals, and the general public have varying perceptions of the expectations and risks of using gene therapy for the treatment of cardiovascular disease. Gene therapists are aware of the importance of selecting the right vector, the right gene, and the right administration procedure for a specific application and for characterization of the heterogeneity of the physiologic response to gene expression. They also recognize the need for large-scale clinical trials to demonstrate short- and long-term safety, in addition to efficacy, for widespread acceptance. Interventional cardiologists are more likely to judge a therapy primarily on its ability to improve cardiovascular pathophysiology and function, although they too will demand safety data. Once convinced of the benefits of a gene therapy, interventional cardiologists will rely on regulatory and reimbursement authorities to approve the procedure. Attitudes of less-specialized physicians toward gene therapy and, specifically, therapeutic angiogenesis will be influenced by the level of clinical trial activity in their country and opinions expressed in the media. However, all will want safety and efficacy data as well as clear guidance on the type of patients who should be referred for treatment. Nurses' roles are set to expand with the introduction of gene-based therapies; most will need further genetics education to rise to these challenges with confidence. The success of a gene therapy will also rely on patients' perceptions and their willingness to receive the treatment. Any misconceptions based on unreliable information sources need to be addressed.

AB - Due to differences in their knowledge base, scientists, health care professionals, and the general public have varying perceptions of the expectations and risks of using gene therapy for the treatment of cardiovascular disease. Gene therapists are aware of the importance of selecting the right vector, the right gene, and the right administration procedure for a specific application and for characterization of the heterogeneity of the physiologic response to gene expression. They also recognize the need for large-scale clinical trials to demonstrate short- and long-term safety, in addition to efficacy, for widespread acceptance. Interventional cardiologists are more likely to judge a therapy primarily on its ability to improve cardiovascular pathophysiology and function, although they too will demand safety data. Once convinced of the benefits of a gene therapy, interventional cardiologists will rely on regulatory and reimbursement authorities to approve the procedure. Attitudes of less-specialized physicians toward gene therapy and, specifically, therapeutic angiogenesis will be influenced by the level of clinical trial activity in their country and opinions expressed in the media. However, all will want safety and efficacy data as well as clear guidance on the type of patients who should be referred for treatment. Nurses' roles are set to expand with the introduction of gene-based therapies; most will need further genetics education to rise to these challenges with confidence. The success of a gene therapy will also rely on patients' perceptions and their willingness to receive the treatment. Any misconceptions based on unreliable information sources need to be addressed.

UR - http://www.scopus.com/inward/record.url?scp=0242627532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242627532&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(03)00964-0

DO - 10.1016/S0002-9149(03)00964-0

M3 - Article

VL - 92

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9 SUPPL. 2

ER -